We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $11.7B
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
+2.84%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$293M
AUM Growth
+$17.2M
Cap. Flow
+$24.2M
Cap. Flow %
8.28%
Top 10 Hldgs %
72.5%
Holding
39
New
5
Increased
13
Reduced
10
Closed
4

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$16.9M
2
GLD icon
SPDR Gold Trust
GLD
+$9.99M
3
BMY icon
Bristol-Myers Squibb
BMY
+$7.07M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$5.76M
5
VIVE
VIVEVE MED INC
VIVE
+$3.8M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$7.93M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$4.74M
3
OMER icon
Omeros
OMER
+$4.49M
4
KITE
Kite Pharma, Inc.
KITE
+$2.85M
5
LPCN icon
Lipocine
LPCN
+$2.44M

Sector Composition

Rank Sector Weight
1 Healthcare 88.39%
2 Miscellaneous 11.61%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$31.7B
$46.2M 15.78%
832,549
-33,830
-4% -$2.13M
INCY icon
2
Incyte
INCY
$25.2B
$31.4M 10.72%
392,236
+12,821
+3% +$995K
BLUE
3
DELISTED
bluebird bio
BLUE
$26.5M 9.05%
47,248
+29,772
+170% +$16.9M
ACHN
4
DELISTED
Achillion Pharmaceuticals
ACHN
$18.9M 6.46%
2,424,136
-134,723
-5% -$1.16M
LJPC
5
DELISTED
La Jolla Pharmaceutical Company
LJPC
$18.8M 6.43%
1,176,146
+7,081
+0.6% +$127K
AVXS
6
DELISTED
AveXis, Inc. Common Stock
AVXS
$18.1M 6.19%
476,367
+2,993
+0.6% +$101K
BMY icon
7
Bristol-Myers Squibb
BMY
$136B
$15.4M 5.27%
209,701
+100,000
+91% +$7.07M
KITE
8
DELISTED
Kite Pharma, Inc.
KITE
$14.3M 4.88%
285,518
-57,985
-17% -$2.85M
SSRG
9
DELISTED
SYMMETRY SURGICAL INC COMMON STK
SSRG
$12.1M 4.14%
922,215
+2,535
+0.3% +$30.6K
GLD icon
10
SPDR Gold Trust
GLD
$149B
$10.5M 3.59%
+83,000
New +$9.99M
ATRA icon
11
Atara Biotherapeutics
ATRA
$92.3M
$10.5M 3.58%
18,635
-290
-2% -$139K
AGEN
12
Agenus
AGEN
$345M
$9.84M 3.36%
123,765
+745
+0.6% +$58.1K
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.51B
$6.35M 2.17%
2,237,066
+263,134
+13% +$817K
TLT icon
14
iShares 20+ Year Treasury Bond ETF
TLT
$46.8B
$6.25M 2.14%
45,000
+15,000
+50% +$1.98M
DRNA
15
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$6.08M 2.08%
2,026,894
– –
ICPT
16
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$5.64M 1.93%
+39,500
New +$5.76M
CLDX icon
17
Celldex Therapeutics
CLDX
$3.07B
$5.55M 1.9%
84,282
+18,324
+28% +$1.16M
OMER icon
18
Omeros
OMER
$1.35B
$5.54M 1.89%
526,788
-364,734
-41% -$4.49M
VIVE
19
DELISTED
VIVEVE MED INC
VIVE
$3.34M 1.14%
+815
New +$3.8M
JO
20
DELISTED
iPath Bloomberg Coffee Subindex Total Return ETN due June 24, 2038
JO
$3.19M 1.09%
+144,200
New +$2.82M
CORI
21
DELISTED
Corium International, Inc.
CORI
$2.96M 1.01%
852,961
+24,629
+3% +$100K
IVTY
22
DELISTED
Invuity, Inc
IVTY
$2.15M 0.74%
226,042
+13,234
+6% +$91.9K
RGNX icon
23
Regenxbio
RGNX
$638M
$1.94M 0.66%
242,784
+1,461
+0.6% +$16.2K
FPRX
24
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.85M 0.63%
44,701
-182,297
-80% -$7.93M
GBT
25
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.61M 0.55%
97,138
-93,843
-49% -$1.89M
1
2

Similar funds

CIM
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

RTW Investments's Q2 2016 Portfolio in Review

As of Q2 2016, RTW Investments held 39 positions worth $293M, up 6.3% from $275M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

RTW Investments deployed $24.2M of net new capital in Q2 2016, opening 5 new positions and adding to 13 existing holdings. Its largest new stake was SPDR Gold Trust: 83,000 shares worth $10.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Five Prime Therapeutics, Inc., an estimated $7.93M trimmed.

  • RTW Investments's largest Q2 2016 buy was SPDR Gold Trust: 83,000 shares worth $10.5M.
  • RTW Investments added most to bluebird bio in Q2 2016, an estimated $16.9M increase.
  • RTW Investments's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $7.93M.
  • RTW Investments fully exited Lipocine in Q2 2016, selling an estimated $2.44M.
  • RTW Investments's ten largest holdings make up 73% of its $293M portfolio in Q2 2016.
  • RTW Investments opened 5 new positions and closed 4 in Q2 2016.
  • RTW Investments's portfolio value rose 6.3% quarter-over-quarter to $293M.

Based on RTW Investments's 13F filing for Q2 2016, filed 15 Aug 2016.